Folic acid to prevent neural tube defects: Scientific advances and public health issues

Current Opinion in Obstetrics and Gynecology

Volumn 8, Issue 6, 1996, Pages 394-397

  Mills, James L ^a   Conley, Mary R ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYSTATHIONINE; FOLIC ACID; HOMOCYSTEINE; METHIONINE SYNTHASE;

CLINICAL TRIAL; DIET SUPPLEMENTATION; FOLATE METABOLISM; HUMAN; NEURAL TUBE DEFECT; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW;

EID: 0030459440     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199612000-00002     Document Type: Review

References (18)

1. Mills JL, Scott JM, Kirke PN, McPartlin JM, Conley MR, Weir DG, Molloy AM, Lee YJ: Homocysteine and neural tube defects. J Nutr 1996, 126:756-760.
2. Centers for Disease Control and Prevention: Prevention program for reducing risk for neural tube defects-South Carolina, 1992-1994. MMWR 1995, 44:141-142.
3. Clark NAC, Fisk NM: Minimal compliance with the Department of Health recommendation for routine folate prophylaxis to prevent foetal neural tube defects. Br J Obstet Gynaecol 1994, 101:709-710.
4. Centers for Disease Control and Prevention: Knowledge and use of folic acid by women of childbearing age - United States, 1995. MMWR 1995, 44:716-717.
5. Fraser FC: Folic acid and neural tube defects [Letter]. Can Med Assoc J 1995, 152:1380-1381.
6. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM: Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med 1993, 86:703-708.
7. Mills JL, Tuomilehto J, Yu KF, Colman N, Blaner WS, Koskela P, Rundle WE, Forman M, Toivanen L, Rhoads GG: Maternal vitamin levels during pregnancies producing infants with neural tube defects. J Pediatr 1992, 120:863-871.
8. Mills JL, Raymond E: Effects of recent research on recommendations for periconceptional folate supplement use. Ann NY Acad Sci 1993, 678:137-145.
9. Steegers-Theunissen R, Boers G, Trijbels FJ, Eskes TK: Neural-tube defects and derangement of homocysteine metabolism [Letter]. N Engl J Med 1991, 324:199-200.
10. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, Scott JM: Homocysteine metabolism in pregnancies complicated by neural tube defects. Lancet 1995, 345:149-151. The homocysteine abnormality in affected pregnancies is described.
11. Steegers-Theunissen RPM, Boers GHJ, Trijbels FJM, Finkelstein JD, Blom HJ, Thomas CMG, Borm GF, Wouters MGAJ, Eskes TKAB: Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Metabolism 1994, 43:1475-1480.
12. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heizer M, Kluijtmans LAJ, van den Henvel LP, Rosen R: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995, 10:111-113.
13. ••]) showing a genetic factor in NTDs.
14. ••]) showing a genetic factor in NTDs.
15. Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, Read AP, Fielding DW: Apparent prevention of neural tube defects by periconceptional vitamin supplementation. Arch Dis Child 1981, 56:911-918.
16. Medical Research Council Vitamin Study Research Group: Prevention of neural-tube defects: results of the Medical Research Council vitamin study. Lancet 1991, 338:131-137.
17. Czeizel AE, Dudas I: Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992, 327:1832-1835.
18. US Food and Drug Administration: Proposed rule. Food standards: amendment of the standards of identity for enriched grain products to require addition of folic acid. Federal Reg 1993, 58:53305-53312.